Anxo Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Anxo Pharmaceutical has a total shareholder equity of NT$1.2B and total debt of NT$705.4M, which brings its debt-to-equity ratio to 61.3%. Its total assets and total liabilities are NT$2.2B and NT$1.0B respectively.
Key information
61.3%
Debt to equity ratio
NT$705.43m
Debt
| Interest coverage ratio | n/a |
| Cash | NT$349.79m |
| Equity | NT$1.15b |
| Total liabilities | NT$1.03b |
| Total assets | NT$2.18b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 6677's short term assets (NT$951.1M) exceed its short term liabilities (NT$533.8M).
Long Term Liabilities: 6677's short term assets (NT$951.1M) exceed its long term liabilities (NT$492.5M).
Debt to Equity History and Analysis
Debt Level: 6677's net debt to equity ratio (30.9%) is considered satisfactory.
Reducing Debt: 6677's debt to equity ratio has reduced from 132% to 61.3% over the past 5 years.
Debt Coverage: 6677's debt is not well covered by operating cash flow (5.3%).
Interest Coverage: Insufficient data to determine if 6677's interest payments on its debt are well covered by EBIT.